Mark Hensley, the Chief Operating Officer of Heron Therapeutics, Inc., has recently reported the acquisition of 15,119 shares of the company’s stock. This transaction, which took place on October 30, 2026, underscores Hensley’s commitment to Heron and reflects his confidence in the company’s future prospects.

Heron Therapeutics, a company focused on pharmaceutical preparations, is known for its innovative approaches in drug development. The company is incorporated in Delaware and operates out of San Diego, California. Hensley’s recent stock purchases may provide insights into the company’s ongoing strategies and market position.

According to the SEC filing, Hensley acquired 11,770 shares through the exercise of restricted stock units (RSUs) and bought an additional 3,349 shares at a price of $0.28 per share. Following these transactions, Hensley holds a total of 182,671 shares of Heron’s common stock.

This update may have implications for various stakeholders, including investors and analysts monitoring Heron’s performance in the competitive pharmaceutical industry. Hensley’s actions could influence market perceptions regarding the company’s strategic direction and potential growth.

Details were not available in the SEC filing regarding future transactions or plans. However, Hensley’s continued investment in Heron Therapeutics suggests a positive outlook for the company.

Details of the Transactions

In the recent SEC filing, it is noted that Hensley acquired 11,770 shares through the exercise of restricted stock units (RSUs) that were granted to him on January 30, 2026. These RSUs have a vesting schedule that allows them to vest in 16 equal quarterly installments, starting one quarter after the grant date. This structured vesting plan indicates a long-term commitment to the company, aligning Hensley’s interests with those of shareholders.

Additionally, Hensley purchased 3,349 shares at a price of $0.28 per share, further demonstrating his belief in the company's potential. Following these transactions, Hensley now owns a total of 182,671 shares of Heron Therapeutics' common stock, reflecting a significant investment in the company.

Company Background

Heron Therapeutics, Inc., incorporated in Delaware, specializes in pharmaceutical preparations and is classified under the Standard Industrial Classification (SIC) code 2834. The company is headquartered in San Diego, California, and operates under the trading symbol HRTX. As of the fiscal year ending December 31, Heron Therapeutics continues to pursue innovative drug development strategies aimed at addressing unmet medical needs.

"Each restricted stock unit represents a contingent right to receive one share of common stock," as noted in the filing, emphasizing the potential value of Hensley’s RSUs as they vest.

While the filing provides detailed information about Hensley’s recent stock transactions, it does not include insights into the company's upcoming projects or financial performance forecasts. Stakeholders may be keen to learn more about Heron's strategic initiatives and market positioning in future disclosures.